Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

Search life-sciences literature (45,103,589 articles, preprints and more)

Search results

1-25 of 44 results

Sort by:

Relevance ^{Relevance: This is determined based on a ranking of criteria including term frequency, rarity of term, recency of article, whether there is a Title or Author field match, etc.}

Times cited

Date

1 2

Identification and validation of tryptophan-related gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma reveals a critical role for PTTG1.
Wang Z, Zhang J, Zuo C, Chen H, Wang L, Xie Y, Ma H, Min S, Wang X, Lian C
Front Immunol, 15:1386427, 31 Jul 2024
Cited by: 0 articles | PMID: 39144144 | PMCID: PMC11321965
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Safety and efficacy of restarting immune checkpoint inhibitors in non-small cell lung cancer patients following immune-related adverse events: a systematic review and meta-analysis.
Tan K, Wang A, Zheng Y, Wang S, Wang C, Li J, Lu X, Dong H, Zheng J, Cui H
Clin Transl Oncol, 26 Jun 2024
Cited by: 0 articles | PMID: 38922538
Add to export list Review
GJB3: a comprehensive biomarker in pan-cancer prognosis and immunotherapy prediction.
Zeng J, Li X, Zhang Y, Zhang B, Wang H, Bao S, Zu L, Zhang H, Cheng Y, Tang Q, Xu X, Xu S, Song Z
Aging (Albany NY), 16(9):7647-7667, 07 May 2024
Cited by: 0 articles | PMID: 38728250 | PMCID: PMC11132019
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Several first-line anti-hypertensives act on fibrosarcoma progression and PD1ab blockade therapy.
Sun J, Zhang C, Su X, Zhou H, Zhou S, Jiang M, Fang B
J Orthop Surg Res, 19(1):147, 19 Feb 2024
Cited by: 0 articles | PMID: 38373964 | PMCID: PMC10875773
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
The biotherapeutic Clostridium butyricum MIYAIRI 588 strain potentiates enterotropism of Rorγt⁺Treg and PD-1 blockade efficacy.
Paz Del Socorro T, Oka K, Boulard O, Takahashi M, Poulin LF, Hayashi A, Chamaillard M
Gut Microbes, 16(1):2315631, 01 Jan 2024
Cited by: 2 articles | PMID: 38385162 | PMCID: PMC10885180
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
The antihypertensive felodipine shows synergistic activity with immune checkpoint blockade and inhibits tumor growth via NFAT1 in LUSC.
Liang SY, Xiao HK
Open Med (Wars), 18(1):20230801, 22 Sep 2023
Cited by: 0 articles | PMID: 37750075 | PMCID: PMC10518203
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Prognostic relevance of tumor‑infiltrating lymphocytes in residual tumor tissue from patients with triple‑negative breast cancer following neoadjuvant chemotherapy: A systematic review and meta‑analysis.
Cao B, Zhang Z, Wang C, Lv X
Oncol Lett, 26(4):441, 24 Aug 2023
Cited by: 3 articles | PMID: 37664648 | PMCID: PMC10472026
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Effectiveness and safety of pembrolizumab for patients with advanced non-small cell lung cancer in real-world studies and randomized controlled trials: A systematic review and meta-analysis.
Yang B, Wang B, Chen Y, Wan N, Xie F, Yang N, Lu L, Xiao W, Yuan J, Li J, Xie B, Ji B
Front Oncol, 13:1044327, 07 Feb 2023
Cited by: 3 articles | PMID: 36824127 | PMCID: PMC9942927
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Comprehensive analysis of the prognosis, tumor microenvironment, and immunotherapy response of SDHs in colon adenocarcinoma.
Nan H, Guo P, Fan J, Zeng W, Hu C, Zheng C, Pan B, Cao Y, Ge Y, Xue X, Li W, Lin K
Front Immunol, 14:1093974, 06 Mar 2023
Cited by: 0 articles | PMID: 36949947 | PMCID: PMC10025334
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Tumor intrinsic and extrinsic functions of CD73 and the adenosine pathway in lung cancer.
Kowash RR, Akbay EA
Front Immunol, 14:1130358, 24 Mar 2023
Cited by: 1 article | PMID: 37033953 | PMCID: PMC10079876
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Blockade of neutrophil recruitment to tumor sites based on sialic acid-modified nanoplatforms enhances the efficacy of checkpoint blockade immunotherapy.
Chen M, Qi Z, Meng X, Wang S, Zheng X, Hu M, Liu X, Song Y, Deng Y
Asian J Pharm Sci, 18(2):100784, 23 Feb 2023
Cited by: 0 articles | PMID: 36968653 | PMCID: PMC10034569
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Immune biology of NSCLC revealed by single-cell technologies: implications for the development of biomarkers in patients treated with immunotherapy.
Wlosik J, Fattori S, Rochigneux P, Goncalves A, Olive D, Chretien AS
Semin Immunopathol, 45(1):29-41, 21 Nov 2022
Cited by: 5 articles | PMID: 36414693 | PMCID: PMC9974692
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS+ CD4+ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer.
Rochigneux P, Lisberg A, Garcia A, Granjeaud S, Madroszyk A, Fattori S, Gonçalves A, Devillier R, Maby P, Salem N, Gorvel L, Chanez B, Gukasyan J, Carroll J, Goldman J, Chretien AS, Olive D, Garon EB
Clin Cancer Res, 28(23):5136-5148, 01 Dec 2022
Cited by: 10 articles | PMID: 36166003 | PMCID: PMC10085054
Add to export list Free full text in Europe PMC
A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world.
Shi Y, Ji M, Jiang Y, Yin R, Wang Z, Li H, Wang S, He K, Ma Y, Wang Z, Lu J, Shi M, Shen B, Zhou G, Leong TL, Wang X, Chen C, Feng J
Transl Lung Cancer Res, 11(6):1051-1068, 01 Jun 2022
Cited by: 9 articles | PMID: 35832459 | PMCID: PMC9271442
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Immune Checkpoint Blockade Outcome in Small-Cell Lung Cancer and Its Relationship With Retinoblastoma Mutation Status and Function.
Dowlati A, Abbas A, Chan T, Henick B, Wang X, Doshi P, Fu P, Patel J, Kuo F, Chang H, Balli D
JCO Precis Oncol, 6:e2200257, 01 Aug 2022
Cited by: 7 articles | PMID: 36044718 | PMCID: PMC9489185
Add to export list Free full text in Europe PMC
The Effects of 6 Common Antidiabetic Drugs on Anti-PD1 Immune Checkpoint Inhibitor in Tumor Treatment.
Zhan ZT, Liu L, Cheng MZ, Gao Y, Zhou WJ
J Immunol Res, 2022:2651790, 18 Aug 2022
Cited by: 5 articles | PMID: 36033393 | PMCID: PMC9410852
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Results of emergency salvage lung resection after chemo- and/or radiotherapy among patients with lung cancer.
Hino H, Utsumi T, Maru N, Matsui H, Taniguchi Y, Saito T, Tsuta K, Murakawa T
Interact Cardiovasc Thorac Surg, 35(1):ivac043, 01 Jun 2022
Cited by: 2 articles | PMID: 35253874 | PMCID: PMC9714598
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects.
Tang S, Qin C, Hu H, Liu T, He Y, Guo H, Yan H, Zhang J, Tang S, Zhou H
Cells, 11(3):320, 19 Jan 2022
Cited by: 53 articles | PMID: 35159131 | PMCID: PMC8834198
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives.
Roccuzzo G, Giordano S, Fava P, Pileri A, Guglielmo A, Tonella L, Sanlorenzo M, Ribero S, Fierro MT, Quaglino P
Front Oncol, 11:733770, 16 Aug 2021
Cited by: 9 articles | PMID: 34485162 | PMCID: PMC8415544
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Immune Checkpoint Inhibitors in Prostate Cancer.
Venkatachalam S, McFarland TR, Agarwal N, Swami U
Cancers (Basel), 13(9):2187, 02 May 2021
Cited by: 38 articles | PMID: 34063238 | PMCID: PMC8125096
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Nanotechnology synergized immunoengineering for cancer.
Chauhan DS, Dhasmana A, Laskar P, Prasad R, Jain NK, Srivastava R, Jaggi M, Chauhan SC, Yallapu MM
Eur J Pharm Biopharm, 163:72-101, 24 Mar 2021
Cited by: 5 articles | PMID: 33774162 | PMCID: PMC8170847
Add to export list Review Free full text in Europe PMC
PD-L1 immunohistochemistry in non-small-cell lung cancer: unraveling differences in staining concordance and interpretation.
Keppens C, Dequeker EM, Pauwels P, Ryska A, 't Hart N, von der Thüsen JH
Virchows Arch, 478(5):827-839, 04 Dec 2020
Cited by: 6 articles | PMID: 33275169 | PMCID: PMC8099807
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs?
Zorko NA, Ryan CJ
Prostate Cancer Prostatic Dis, 24(4):986-996, 25 May 2021
Cited by: 9 articles | PMID: 34035459 | PMCID: PMC8613314
Add to export list Review
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer.
Cabioglu N, Onder S, Oner G, Karatay H, Tukenmez M, Muslumanoglu M, İgci A, Eralp Y, Aydiner A, Saip P, Yavuz E, Ozmen V
BMC Cancer, 21(1):357, 06 Apr 2021
Cited by: 9 articles | PMID: 33823818 | PMCID: PMC8025357
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Identification of an Individualized Immune-Related Prognostic Risk Score in Lung Squamous Cell Cancer.
Zhuang Y, Li S, Liu C, Li G
Front Oncol, 11:546455, 03 Mar 2021
Cited by: 9 articles | PMID: 33747902 | PMCID: PMC7966508
Add to export list
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC

1-25 of 44 results

1 2

Search life-sciences literature (45,103,589 articles, preprints and more)

Search results

Identification and validation of tryptophan-related gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma reveals a critical role for PTTG1.

Safety and efficacy of restarting immune checkpoint inhibitors in non-small cell lung cancer patients following immune-related adverse events: a systematic review and meta-analysis.

GJB3: a comprehensive biomarker in pan-cancer prognosis and immunotherapy prediction.

Several first-line anti-hypertensives act on fibrosarcoma progression and PD1ab blockade therapy.

The biotherapeutic Clostridium butyricum MIYAIRI 588 strain potentiates enterotropism of Rorγt⁺Treg and PD-1 blockade efficacy.

The antihypertensive felodipine shows synergistic activity with immune checkpoint blockade and inhibits tumor growth via NFAT1 in LUSC.

Prognostic relevance of tumor‑infiltrating lymphocytes in residual tumor tissue from patients with triple‑negative breast cancer following neoadjuvant chemotherapy: A systematic review and meta‑analysis.

Effectiveness and safety of pembrolizumab for patients with advanced non-small cell lung cancer in real-world studies and randomized controlled trials: A systematic review and meta-analysis.

Comprehensive analysis of the prognosis, tumor microenvironment, and immunotherapy response of SDHs in colon adenocarcinoma.

Tumor intrinsic and extrinsic functions of CD73 and the adenosine pathway in lung cancer.

Blockade of neutrophil recruitment to tumor sites based on sialic acid-modified nanoplatforms enhances the efficacy of checkpoint blockade immunotherapy.

Immune biology of NSCLC revealed by single-cell technologies: implications for the development of biomarkers in patients treated with immunotherapy.

Mass Cytometry Reveals Classical Monocytes, NK Cells, and ICOS+ CD4+ T Cells Associated with Pembrolizumab Efficacy in Patients with Lung Cancer.

A cohort study of the efficacy and safety of immune checkpoint inhibitors plus anlotinib versus immune checkpoint inhibitors alone as the treatment of advanced non-small cell lung cancer in the real world.

Immune Checkpoint Blockade Outcome in Small-Cell Lung Cancer and Its Relationship With Retinoblastoma Mutation Status and Function.

The Effects of 6 Common Antidiabetic Drugs on Anti-PD1 Immune Checkpoint Inhibitor in Tumor Treatment.

Results of emergency salvage lung resection after chemo- and/or radiotherapy among patients with lung cancer.

Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Progress, Challenges, and Prospects.

Immune Check Point Inhibitors in Primary Cutaneous T-Cell Lymphomas: Biologic Rationale, Clinical Results and Future Perspectives.

Immune Checkpoint Inhibitors in Prostate Cancer.

Nanotechnology synergized immunoengineering for cancer.

PD-L1 immunohistochemistry in non-small-cell lung cancer: unraveling differences in staining concordance and interpretation.

Novel immune engagers and cellular therapies for metastatic castration-resistant prostate cancer: do we take a BiTe or ride BiKEs, TriKEs, and CARs?

TIM3 expression on TILs is associated with poor response to neoadjuvant chemotherapy in patients with locally advanced triple-negative breast cancer.

Identification of an Individualized Immune-Related Prognostic Risk Score in Lung Squamous Cell Cancer.

Partnerships & funding